Macrophage-Directed Cancer Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2382

Special Issue Editor

E-Mail Website
Guest Editor
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 41346 Gothenburg, Sweden
Interests: macrophage; cancer; immunotherapy; monoclonal antibodies

Special Issue Information

Dear Colleagues,

Welcome to our highly acclaimed Special Issue entitled "Macrophage-Directed Cancer Immunotherapy", which explores the dynamic landscape of using macrophages in innovative cancer treatments. The objective of this Special Issue is to consolidate the latest research focusing on the central role of macrophages in the formation of tumor immunity and their potential as therapeutic targets. We welcome contributions that clarify the modulation, polarization, and interactions within the tumor microenvironment and their manipulation for effective immunotherapy. The scope of this Special Issue includes research on novel strategies, preclinical and clinical advances, biomarkers, and the evolving landscape of macrophage-based interventions in cancer. Join us in deciphering the complexity and promises of macrophage-centered immunotherapy to restructure the cancer treatment landscape. We invite you to submit your research papers, reviews, editorials, and communications to this Special Issue to advance the boundaries of cancer immunotherapy.

Dr. Zahra Payandeh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • macrophage
  • cancer
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


49 pages, 2525 KiB  
Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review
by Hassan Mesgari, Samar Esmaelian, Kamyar Nasiri, Shabnam Ghasemzadeh, Parisa Doroudgar and Zahra Payandeh
Cancers 2023, 15(23), 5600; - 27 Nov 2023
Cited by 1 | Viewed by 2206
Oral squamous cell carcinoma (OSCC) is a prevalent and significant type of oral cancer that has far-reaching health implications worldwide. Epigenetics, a field focused on studying heritable changes in gene expression without modifying DNA sequence, plays a pivotal role in OSCC. Epigenetic changes, [...] Read more.
Oral squamous cell carcinoma (OSCC) is a prevalent and significant type of oral cancer that has far-reaching health implications worldwide. Epigenetics, a field focused on studying heritable changes in gene expression without modifying DNA sequence, plays a pivotal role in OSCC. Epigenetic changes, encompassing DNA methylation, histone modifications, and miRNAs, exert control over gene activity and cellular characteristics. In OSCC, aberrant DNA methylation of tumor suppressor genes (TSG) leads to their inactivation, subsequently facilitating tumor growth. As a result, distinct patterns of gene methylation hold promise as valuable biomarkers for the detection of OSCC. Oral cancer treatment typically involves surgery, radiation therapy, and chemotherapy, but even with these treatments, cancer cells cannot be effectively targeted and destroyed. Researchers are therefore exploring new methods to target and eliminate cancer cells. One promising approach is the use of epigenetic modifiers, such as DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors, which have been shown to modify abnormal epigenetic patterns in OSCC cells, leading to the reactivation of TSGs and the suppression of oncogenes. As a result, epigenetic-targeted therapies have the potential to directly alter gene expression and minimize side effects. Several studies have explored the efficacy of such therapies in the treatment of OSCC. Although studies have investigated the efficacy of epigenetic therapies, challenges in identifying reliable biomarkers and developing effective combination treatments are acknowledged. Of note, epigenetic mechanisms play a significant role in drug resistance in OSCC and other cancers. Aberrant DNA methylation can silence tumor suppressor genes, while alterations in histone modifications and chromatin remodeling affect gene expression related to drug metabolism and cell survival. Thus, understanding and targeting these epigenetic processes offer potential strategies to overcome drug resistance and improve the efficacy of cancer treatments in OSCC. This comprehensive review focuses on the complex interplay between epigenetic alterations and OSCC cells. This will involve a deep dive into the mechanisms underlying epigenetic modifications and their impact on OSCC, including its initiation, progression, and metastasis. Furthermore, this review will present the role of epigenetics in the treatment and diagnosis of OSCC. Full article
(This article belongs to the Special Issue Macrophage-Directed Cancer Immunotherapy)
Show Figures

Figure 1

Back to TopTop